HYBIO
30019921.496.39% ( +1.29 )
HYBIO (300199)
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The comp...
- Open
- 20.29
- High
- 21.90
- Low
- 20.29
- Prev. Close
- 20.20
- Volume
- 352.96K
- Turnover
- 755.58M
- Avg Price
- 21.41
- Bid/Ask Ratio
- --
- Amplitude
- 7.97%
- 52wk High
- 31.19
- Volume Ratio
- 2.02
- Turnover Ratio
- 4.00%
HYBIO Analyst Rating
View MoreForecast & Rating
Oct 22, 2020Price forecast
¥15.10-29.57%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Yicai · Jul 1 at 06:31 AM
China's Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug Tirzepatide
- Zhitong · Sep 25, 2025 at 07:01 AM
HYBIO plans to raise no more than 968 million yuan through a private placement for multiple projects and to supplement working capital
- Zhitong · Sep 25, 2025 at 06:30 AM
HYBIO: Plans to issue A-share stocks
- Zhitong · Aug 21, 2025 at 08:51 PM
The industrial hemp sector has undergone significant adjustments, and GETM has hit the daily limit down
- Zhitong · Aug 21, 2025 at 05:54 AM
HYBIO released its performance for the first half of the year, turning a loss into a profit of 145 million yuan
- Zhitong · Aug 21, 2025 at 03:58 AM
HYBIO: Acetate Atosiban Injection has obtained marketing authorization in Vietnam
